NetScientific plc
(‘NetScientific’ or the ‘Group’)
Research Programme in DNA Sequencing
NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with a research institute in the United States.
This programme is in a fast-growing, valuable and very competitive field. Notwithstanding the crowded IP landscape, feedback from the US Patent Office on the initial filings is encouraging.
|
For further information, please contact |
|
|
NetScientific plc |
Tel: +44 (0) 20 3590 8877 |
|
Farad Azima, Chief Executive Officer |
|
|
Peter Thoms, Chief Financial Officer |
|
|
Liberum (Nomad & Broker) |
Tel: +44 (0) 20 3100 2222 |
|
Chris Bowman / Christopher Britton / Thomas Bective |
|
|
Bell Pottinger |
Tel: +44 (0) 20 7861 3232 |
|
Daniel de Belder |
Company website: www.netscientific.net
ABOUT NETSCIENTIFIC
NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples’ lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.
END
MSCSSSFLFFLSEEW
